Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma
Abstract Background Bexarotene, which has been approved for use in Japan since 2016, is an effective drug for cutaneous T-cell lymphoma; however, careful management is imperative because of its adverse events. We previously demonstrated the severity of bexarotene-associated hypertriglyceridemia and...
Saved in:
Main Authors: | Akimasa Sanagawa (Author), Tomoaki Hayakawa (Author), Aya Yamamoto (Author), Yuji Hotta (Author), Yoko Furukawa-Hibi (Author), Akimichi Morita (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats
by: Shuyue Ren, et al.
Published: (2020) -
Photodegradation of Bexarotene and Its Implication for Cytotoxicity
by: Agata Kryczyk-Poprawa, et al.
Published: (2021) -
Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial
by: Chalid Assaf, et al.
Published: (2023) -
CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas
by: Jun Yamamoto, et al.
Published: (2023) -
Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement
by: Fu Xiao, et al.
Published: (2022)